From: Rafal Smigrodzki (rafal@smigrodzki.org)
Date: Thu Feb 13 2003 - 13:56:53 MST
gts wrote:
> Because this discussion list is not a support list for Parkinson's
> Disease patients, I suggest we stop focusing only on PD and start
> focusing on the likely risks/benefits of selegiline in healthy and
> aging people.
### I am not aware of any class I or class II evidence for life extension in
healthy, non-PD humans. Animal studies and uncontrolled trials can be
intriguing and even entertaining, but I personally would not spend my money
on anything that has only class IV or animal research data going for it.
There are other options, like Aggrenox (shown by class I evidence to reduce
stroke by almost 30% in susceptible populations), the statins that I already
mentioned, and ACE inhibitors, shown in the HOPE and other trials to reduce
stroke, and myocardial infarction.
Of course, I do support to the right of every customer to interpret the
available data as he or she wishes, and I do not get upset if their
conclusions, which they support with their own money, are different than
mine. However, I always insist on the balanced portrayal of the validity of
in vitro data, animal studies, uncontrolled human and finally, controlled
human studies with directly important endpoints (e.g. 5-year survival,
stroke and disability, as opposed to secondary indicators, such as blood
pressure, or occurrence of PVC's).
Rafal
This archive was generated by hypermail 2.1.5 : Fri Feb 14 2003 - 08:12:21 MST